Skip to Content


In the US, Lapatinib (lapatinib systemic) is a member of the following drug classes: EGFR inhibitors, HER2 inhibitors and is used to treat Breast Cancer and Breast Cancer - Metastatic.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Cytostatic agent

Tyrosine kinase inhibitor

Chemical Names

N-[3-Chlor-4-(3-fluorbenzyloxy)phenyl]-6-{5-[4-(metylsulfonyl)-2-azabutyl]-2-furyl}chinazolin-4-amin (IUPAC)

N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(metylsulfonyl)etyl]amino}metyl)-2-furyl]quinazolin-4-amine (WHO)

4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)metoxy)phenyl)-6-(5-(((2-(metylsulfonyl)etyl)amino)metyl)-2-furanyl)-

Foreign Names

  • Lapatinibum (Latin)
  • Lapatinib (German)
  • Lapatinib (French)
  • Lapatinib (Spanish)

Generic Names

Brand Names

  • Tykerb
    GlaxoSmithKline, Ecuador; GlaxoSmithKline, Egypt; GSK, Turkey
  • Tyverb
    Glaxo Group, Hungary; GlaxoSmithKline, Portugal; GlaxoSmithKline, Romania; GlaxoSmithKline, Slovakia; GSK, Belgium; Novartis Europharm, Slovenia; Wellcome Limited, Bosnia & Herzegowina
  • Tykerb
    Aspen Pharmacare, South Africa; Glaxo Smithkline, Lebanon; GlaxoSmithKline, Argentina; GlaxoSmithKline, Australia; GlaxoSmithKline, Bangladesh; GlaxoSmithKline, Canada; GlaxoSmithKline, Chile; GlaxoSmithKline, Colombia; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Indonesia; GlaxoSmithKline, Israel; GlaxoSmithKline, Japan; GlaxoSmithKline, Mexico; GlaxoSmithKline, Malaysia; GlaxoSmithKline, New Zealand; GlaxoSmithKline, Oman; GlaxoSmithKline, Philippines; GlaxoSmithKline, Singapore; GlaxoSmithKline, Thailand; GlaxoSmithKline, Taiwan; GlaxoSmithKline, United States; GlaxoSmithKline, Peru
  • Tyverb
    Glaxo Group, Austria; Glaxo Group, Greece; Glaxo Group, Poland; Glaxo Wellcome, Serbia; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Spain; GlaxoSmithKline, Finland; GlaxoSmithKline, Georgia; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Ireland; GlaxoSmithKline, Iceland; GlaxoSmithKline, Italy; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, Sweden; GlaxoSmithKline UK, United Kingdom; Novartis, France; Novartis Pharma, Switzerland


BANBritish Approved Name
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.